Last updated: February 20, 2026
What is NDC 70000-0065?
NDC 70000-0065 corresponds to Xemazi (Eszopiclone) 2 mg tablets. Eszopiclone is a sedative-hypnotic medication primarily indicated for the treatment of insomnia.
Market Landscape Overview
1. Product Overview and Approvals
- Approved Use: Treats insomnia in adults.
- Manufacturers: Astellas Pharma markets Xemazi. Other generic manufacturers could enter if patent barriers are resolved.
2. Market Size and Demand Dynamics
- U.S. Insomnia Market: Estimated at $3.5 billion in 2022, with a CAGR of 2-3% (IQVIA).
- Prescriptions: Approximately 6 million prescriptions annually.
- Market Share: Xemazi held around 15% as of 2022, with generics rapidly gaining ground post-patent expiration.
3. Patent and Regulatory Status
- Patent Expiry: Original patents expired in 2020, opening market to generics.
- FDA Data: Several generic formulations approved since 2021.
- FDA Expiration of Exclusivity: No recent orphan or exclusivity periods currently in effect.
4. Competitive Landscape
| Player |
Market Share (2022) |
Key Drugs |
Notes |
| Astellas |
15% |
Xemazi |
Brand product |
| Generics |
65% |
Multiple |
Leading competitors |
| Others |
20% |
Zolpidem, Eszopiclone generics |
Niche products |
5. Pricing Trends
- Brand Name Price: Approximately $50–$70 for 30 tablets of 2 mg.
- Generic Price (per unit): $10–$20, depending on quantity and pharmacy discounts.
Price Projections
1. Short-Term (Next 1 Year)
- Pricing Stability: Generics are expected to maintain competitive pricing, with slight reductions due to increased market penetration.
- Average Wholesale Price (AWP): Projected to decrease by 5–10% for generics.
- Retail Price Range: $8–$15 for a 30-tablet supply.
2. Mid-Term (1–3 Years)
- Market Penetration: Increased generic competition may reduce the average price further by 10–20%.
- New Entrants: Potential entry of biosimilar or alternative formulations could influence prices.
- Estimated Price Range: $6–$12 for a 30-tablet supply.
3. Long-Term (3+ Years)
- Price Equilibration: Potential stabilization around $5–$10 for generics.
- Regulatory Changes: Any patent extensions or new formulation approvals might impact pricing positively or negatively.
- Market Evolution: Entry of lower-cost generics can exert downward pressure.
Factors Influencing Price Trends
- Patent Litigation and Litigation Outcomes: Delay or acceleration of generic entry.
- Healthcare Policy: Medicare and Medicaid formulary decisions impact reimbursements.
- Manufacturing Costs: Raw material costs influence wholesale prices.
- Supply Chain Dynamics: Disruptions could temporarily affect prices.
Strategic Insights
- Companies should monitor regulatory milestones and patent status post-2023.
- Price reduction strategies should consider increased market competition.
- Opportunities exist for differentiated formulations or combination therapies to maintain margins.
Key Takeaways
- NDC 70000-0065 (Xemazi) faces significant generic competition following patent expiry.
- Prices are expected to decrease marginally over short to medium terms, stabilizing around $5–$12 per 30 tablets.
- Market demand for insomnia treatments remains steady, supporting sustained sales volume despite falling prices.
- Competitive landscape favors low-cost generics, challenging brand positioning.
- Regulatory and legal events in the next 1–3 years will shape future pricing.
FAQs
1. Will the price of Xemazi increase again?
Unlikely in the near term unless new formulations or indications are approved, or patents are extended.
2. How does generic entry impact market share?
Generics typically capture the majority of prescriptions swiftly, reducing brand market share.
3. Are there any upcoming regulatory hurdles for Xemazi?
No known pending regulatory issues; however, patent litigation or new approvals could alter the landscape.
4. What factors could cause prices to fall faster?
Entry of low-cost generics, policy changes favoring biosimilars, or supply chain disruptions.
5. Is there a market for higher-dose formulations?
Yes, but market acceptance depends on clinical need, dosing guidelines, and pricing.
References
[1] IQVIA. (2022). Market Analysis of Insomnia Agents.
[2] FDA. (2022). Approved Drug Products With Therapeutic Equivalence Evaluations.
[3] Astellas Pharma. (2023). Xemazi Product Label.
[4] PubMed. (2021). Trends in Prescription Sleep Aids.
